These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 17465254

  • 1. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
    Ioannou M, Demertzis N, Iakovidou I, Kottakis S.
    Anticancer Res; 2007; 27(2):1143-7. PubMed ID: 17465254
    [Abstract] [Full Text] [Related]

  • 2. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
    Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L.
    Cancer; 2002 Dec 01; 95(11):2373-9. PubMed ID: 12436445
    [Abstract] [Full Text] [Related]

  • 3. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN.
    Reprod Sci; 2008 Sep 01; 15(7):673-7. PubMed ID: 18492696
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
    Liegl B, Leithner A, Bauernhofer T, Windhager R, Guelly C, Regauer S, Beham A.
    Histopathology; 2006 Dec 01; 49(6):576-81. PubMed ID: 17163842
    [Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 6. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Mar 01; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 7. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Gonçalves A, Monges G, Yang Y, Palmerini F, Dubreuil P, Noguchi T, Jacquemier J, Di Stefano D, Delpero JR, Sobol H, Bertucci F.
    J Natl Cancer Inst; 2006 Apr 19; 98(8):562-3. PubMed ID: 16622127
    [No Abstract] [Full Text] [Related]

  • 8. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM.
    Cancer; 2003 Aug 15; 98(4):758-64. PubMed ID: 12910520
    [Abstract] [Full Text] [Related]

  • 9. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.
    J Clin Oncol; 2006 Mar 01; 24(7):1195-203. PubMed ID: 16505440
    [Abstract] [Full Text] [Related]

  • 10. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct 01; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 11. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK.
    Pathol Res Pract; 2007 Oct 01; 203(3):127-34. PubMed ID: 17298867
    [Abstract] [Full Text] [Related]

  • 12. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA.
    Cancer; 2006 May 01; 106(9):2005-11. PubMed ID: 16565971
    [Abstract] [Full Text] [Related]

  • 13. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG, Imatinib Target Exploration Consortium Study B2225.
    Clin Cancer Res; 2008 May 01; 14(9):2717-25. PubMed ID: 18451237
    [Abstract] [Full Text] [Related]

  • 14. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL.
    J Clin Oncol; 2005 Jan 20; 23(3):585-90. PubMed ID: 15659505
    [Abstract] [Full Text] [Related]

  • 15. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA.
    Anticancer Drugs; 2006 Jul 20; 17(6):649-55. PubMed ID: 16917210
    [Abstract] [Full Text] [Related]

  • 16. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, Estevez-Schwarz L, Mawrin C, Friedrich RE, Mautner VF, von Deimling A.
    Carcinogenesis; 2006 Mar 20; 27(3):664-71. PubMed ID: 16357008
    [Abstract] [Full Text] [Related]

  • 17. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
    Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S, Israel Glivec in Solid Tumors Study Group.
    Endocr Relat Cancer; 2006 Jun 20; 13(2):535-40. PubMed ID: 16728580
    [Abstract] [Full Text] [Related]

  • 18. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
    Orzan F, Terreni MR, Longoni M, Boari N, Mortini P, Doglioni C, Riva P.
    Oncol Rep; 2007 Jul 20; 18(1):249-52. PubMed ID: 17549375
    [Abstract] [Full Text] [Related]

  • 19. [Imatinib and solid tumours].
    Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.
    Bull Cancer; 2008 Jan 20; 95(1):99-106. PubMed ID: 18230575
    [Abstract] [Full Text] [Related]

  • 20. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
    Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA.
    Anticancer Res; 2010 Feb 20; 30(2):547-52. PubMed ID: 20332468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.